Multiple Catalysts Ahead For Nektar Therapeutics
Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in H1'25. NKTR-255 is showing promising results in multiple oncology trials, although these are only small studies. NKTR-255 also has a potential near-term readout in the JAVELIN Bladder Medley study, although there is competition.
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago.
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler has initiated coverage on Nektar Therapeutics Inc NKTR, citing the company's lead asset rezpegaldesleukin's (REZPEG) differentiated mechanism of action.
What Makes Nektar (NKTR) a New Buy Stock
Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.27 per share a year ago.
